Results 221 to 230 of about 97,750 (296)

Implantation of human mesenchymal stromal cell pellet for therapeutic angiogenesis. [PDF]

Cytotherapy
Mammoto A, Kyi P, Scheer M, Mammoto T.
europepmc   +1 more source

Breast implants

, 2014
openaire   +1 more source

Clinical efficacy of CT-guided iodine-125 seed brachytherapy in unresectable locoregionally recurrent breast cancer. [PDF]

J Contemp Brachytherapy
Ji L, Zhang W, Hao S, Wang Z, Zhang G.
europepmc   +1 more source

Surgical site infection: Evidence Update [PDF]

, 2013
Collier, Mark, Farrington, Mark, Gould, Kate, Kiernan, Martin, Leaper, David J., Reed, Mike, Tanner, Judith   +6 more
core  

HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma

International Journal of Cancer, EarlyView.
What's New? Ovarian clear cell carcinoma is highly associated with hypoxia. Hypoxia‐inducible factor 2A (HIF2A) is a key regulator of hypoxic responses, but its role in ovarian clear cell carcinoma remains unclear. This study demonstrated the unfavorable prognostic significance of HIF2A expression in ovarian clear cell carcinoma.
Mengxin Jiang, Ken Yamaguchi, Kohei Hamada, Yuko Hosoe, Yuka Mise, Sachiko Kitamura, Zhihong Liu, Hairong Wei, Zhenhai Gao, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Rin Mizuno, Taito Miyamoto, Junzo Hamanishi, Masaki Mandai   +15 more
wiley   +1 more source

Development and Pilot in Vivo Testing of a Protocol for PLGA-Vancomycin Coatings on PTFE Used as Silicone-Implant Analogs. [PDF]

Medicina (Kaunas)
Negrilă AA, Nica O, Ciocîlteu MV, Bită A, Nicolicescu C, Popescu AB, Ciurea ME.   +6 more
europepmc   +1 more source

Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer

International Journal of Cancer, EarlyView.
What's New? Epithelial ovarian cancer (EOC) is a severe malignancy with few effective treatment options. While the mechanisms remain unclear, changes in lipid metabolism may fuel tumor growth and EOC progression, offering a possible path for new treatments.
Hitomi Sakaguchi‐Mukaida, Kosuke Hiramatsu, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Tadashi Iwamiya, Shinya Matsuzaki, Tetsuji Naka, Yutaka Ueda, Tadashi Kimura, Michiko Kodama   +10 more
wiley   +1 more source

A lung specific escape of intravascular metastatic breast cancer cells from cytotoxic T cell killing. [PDF]

Front Immunol
Kizner M, Levi N, Sochen C, Ryvkin J, Regev O, Zarbock A, Eisenbach L, Biton M, Alon R.   +8 more
europepmc   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Interstitial pneumonitis following the implantation of a paclitaxel-eluting stent in a patient with peripheral arterial disease. [PDF]

J Vasc Surg Cases Innov Tech
Haga M, Iwata Y, Nitta J, Akasaka J.
europepmc   +1 more source